ESMOLOL HYDROCHLORIDE MEDSURGE esmolol hydrochloride 100 mg/10 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

esmolol hydrochloride medsurge esmolol hydrochloride 100 mg/10 ml solution for injection vial

medsurge pharma pty ltd - esmolol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate trihydrate; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - esmolol hydrochloride medsurge is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride medsurge is also indicated in non-compensatory sinus tachycardia where, in the physician?s judgement, the rapid heart rate requires specific intervention. esmolol hydrochloride medsurge is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

LECTEVA levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 175 mg; carbidopa monohydrate, quantity: 47.2 mg (equivalent: carbidopa, qty 43.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 150 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; iron oxide red; carmoisine aluminium lake - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 125 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; allura red ac aluminium lake; carmine - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

ESTROFEM estradiol (as hemihydrate) 2mg tablet dial dispenser pack Australia - English - Department of Health (Therapeutic Goods Administration)

estrofem estradiol (as hemihydrate) 2mg tablet dial dispenser pack

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; indigo carmine; macrogol 400 - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

ESTROFEM estradiol (as hemihydrate) 1mg tablet dial dispenser pack Australia - English - Department of Health (Therapeutic Goods Administration)

estrofem estradiol (as hemihydrate) 1mg tablet dial dispenser pack

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 1.03 mg (equivalent: estradiol, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red; propylene glycol - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.